Report Detail

Pharma & Healthcare Global Breast Cancer Targeted Drug Market Research Report 2022

  • RnM4490111
  • |
  • 07 September, 2022
  • |
  • Global
  • |
  • 92 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Description:
Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer.

Highlights

The global Breast Cancer Targeted Drug market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Breast Cancer Targeted Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Breast Cancer Targeted Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Breast Cancer Targeted Drug in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Breast Cancer Targeted Drug include Eli Lilly and Company, Roche, Merck & Co., Novartis, Pfizer, Merck KGaA, Astellas, Janssen Biotech and Bristol-Myers Squibb, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, Brand Drugs, which accounted for % of the global market of Breast Cancer Targeted Drug in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Breast Cancer Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Breast Cancer Targeted Drug.

The Breast Cancer Targeted Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Breast Cancer Targeted Drug market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Breast Cancer Targeted Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Eli Lilly and Company

Roche

Merck & Co.

Novartis

Pfizer

Merck KGaA

Astellas

Janssen Biotech

Bristol-Myers Squibb

Gilead Sciences

Product Type Insights

Global markets are presented by Breast Cancer Targeted Drug type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Breast Cancer Targeted Drug are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Breast Cancer Targeted Drug segment by Type

Brand Drugs

Generic Drug

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the Breast Cancer Targeted Drug market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Breast Cancer Targeted Drug market.

Breast Cancer Targeted Drug Segment by Application

Hospital

Retail Pharmacy

Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Breast Cancer Targeted Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Breast Cancer Targeted Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Breast Cancer Targeted Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Breast Cancer Targeted Drug industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Breast Cancer Targeted Drug.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Breast Cancer Targeted Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue and gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.


Table of content:

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
    • 1.2.1 Global Breast Cancer Targeted Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
  • 1.2.2 Brand Drugs
  • 1.2.3 Generic Drug
  • 1.3 Market by Application
  • 1.3.1 Global Breast Cancer Targeted Drug Market Share by Application: 2017 VS 2021 VS 2028
  • 1.3.2 Hospital
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered
  • 2 Global Growth Trends

    • 2.1 Global Breast Cancer Targeted Drug Market Perspective (2017-2028)
    • 2.2 Breast Cancer Targeted Drug Growth Trends by Region
    • 2.2.1 Breast Cancer Targeted Drug Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Breast Cancer Targeted Drug Historic Market Size by Region (2017-2022)
  • 2.2.3 Breast Cancer Targeted Drug Forecasted Market Size by Region (2023-2028)
  • 2.3 Breast Cancer Targeted Drug Market Dynamics
  • 2.3.1 Breast Cancer Targeted Drug Industry Trends
  • 2.3.2 Breast Cancer Targeted Drug Market Drivers
  • 2.3.3 Breast Cancer Targeted Drug Market Challenges
  • 2.3.4 Breast Cancer Targeted Drug Market Restraints
  • 3 Competition Landscape by Key Players

    • 3.1 Global Top Breast Cancer Targeted Drug Players by Revenue
    • 3.1.1 Global Top Breast Cancer Targeted Drug Players by Revenue (2017-2022)
  • 3.1.2 Global Breast Cancer Targeted Drug Revenue Market Share by Players (2017-2022)
  • 3.2 Global Breast Cancer Targeted Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Breast Cancer Targeted Drug Revenue
  • 3.4 Global Breast Cancer Targeted Drug Market Concentration Ratio
  • 3.4.1 Global Breast Cancer Targeted Drug Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Breast Cancer Targeted Drug Revenue in 2021
  • 3.5 Breast Cancer Targeted Drug Key Players Head office and Area Served
  • 3.6 Key Players Breast Cancer Targeted Drug Product Solution and Service
  • 3.7 Date of Enter into Breast Cancer Targeted Drug Market
  • 3.8 Mergers & Acquisitions, Expansion Plans
  • 4 Breast Cancer Targeted Drug Breakdown Data by Type

    • 4.1 Global Breast Cancer Targeted Drug Historic Market Size by Type (2017-2022)
    • 4.2 Global Breast Cancer Targeted Drug Forecasted Market Size by Type (2023-2028)

    5 Breast Cancer Targeted Drug Breakdown Data by Application

    • 5.1 Global Breast Cancer Targeted Drug Historic Market Size by Application (2017-2022)
    • 5.2 Global Breast Cancer Targeted Drug Forecasted Market Size by Application (2023-2028)

    6 North America

    • 6.1 North America Breast Cancer Targeted Drug Market Size (2017-2028)
    • 6.2 North America Breast Cancer Targeted Drug Market Size by Country (2017-2022)
    • 6.3 North America Breast Cancer Targeted Drug Market Size by Country (2023-2028)
    • 6.4 United States
    • 6.5 Canada

    7 Europe

    • 7.1 Europe Breast Cancer Targeted Drug Market Size (2017-2028)
    • 7.2 Europe Breast Cancer Targeted Drug Market Size by Country (2017-2022)
    • 7.3 Europe Breast Cancer Targeted Drug Market Size by Country (2023-2028)
    • 7.4 Germany
    • 7.5 France
    • 7.6 U.K.
    • 7.7 Italy
    • 7.8 Russia
    • 7.9 Nordic Countries

    8 Asia-Pacific

    • 8.1 Asia-Pacific Breast Cancer Targeted Drug Market Size (2017-2028)
    • 8.2 Asia-Pacific Breast Cancer Targeted Drug Market Size by Country (2017-2022)
    • 8.3 Asia-Pacific Breast Cancer Targeted Drug Market Size by Country (2023-2028)
    • 8.4 China
    • 8.5 Japan
    • 8.6 South Korea
    • 8.7 Southeast Asia
    • 8.8 India
    • 8.9 Australia

    9 Latin America

    • 9.1 Latin America Breast Cancer Targeted Drug Market Size (2017-2028)
    • 9.2 Latin America Breast Cancer Targeted Drug Market Size by Country (2017-2022)
    • 9.3 Latin America Breast Cancer Targeted Drug Market Size by Country (2023-2028)
    • 9.4 Mexico
    • 9.5 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa Breast Cancer Targeted Drug Market Size (2017-2028)
    • 10.2 Middle East & Africa Breast Cancer Targeted Drug Market Size by Country (2017-2022)
    • 10.3 Middle East & Africa Breast Cancer Targeted Drug Market Size by Country (2023-2028)
    • 10.4 Turkey
    • 10.5 Saudi Arabia
    • 10.6 UAE

    11 Key Players Profiles

    • 11.1 Eli Lilly and Company
    • 11.1.1 Eli Lilly and Company Company Detail
  • 11.1.2 Eli Lilly and Company Business Overview
  • 11.1.3 Eli Lilly and Company Breast Cancer Targeted Drug Introduction
  • 11.1.4 Eli Lilly and Company Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.1.5 Eli Lilly and Company Recent Development
  • 11.2 Roche
  • 11.2.1 Roche Company Detail
  • 11.2.2 Roche Business Overview
  • 11.2.3 Roche Breast Cancer Targeted Drug Introduction
  • 11.2.4 Roche Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.2.5 Roche Recent Development
  • 11.3 Merck & Co.
  • 11.3.1 Merck & Co. Company Detail
  • 11.3.2 Merck & Co. Business Overview
  • 11.3.3 Merck & Co. Breast Cancer Targeted Drug Introduction
  • 11.3.4 Merck & Co. Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.3.5 Merck & Co. Recent Development
  • 11.4 Novartis
  • 11.4.1 Novartis Company Detail
  • 11.4.2 Novartis Business Overview
  • 11.4.3 Novartis Breast Cancer Targeted Drug Introduction
  • 11.4.4 Novartis Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.4.5 Novartis Recent Development
  • 11.5 Pfizer
  • 11.5.1 Pfizer Company Detail
  • 11.5.2 Pfizer Business Overview
  • 11.5.3 Pfizer Breast Cancer Targeted Drug Introduction
  • 11.5.4 Pfizer Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.5.5 Pfizer Recent Development
  • 11.6 Merck KGaA
  • 11.6.1 Merck KGaA Company Detail
  • 11.6.2 Merck KGaA Business Overview
  • 11.6.3 Merck KGaA Breast Cancer Targeted Drug Introduction
  • 11.6.4 Merck KGaA Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.6.5 Merck KGaA Recent Development
  • 11.7 Astellas
  • 11.7.1 Astellas Company Detail
  • 11.7.2 Astellas Business Overview
  • 11.7.3 Astellas Breast Cancer Targeted Drug Introduction
  • 11.7.4 Astellas Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.7.5 Astellas Recent Development
  • 11.8 Janssen Biotech
  • 11.8.1 Janssen Biotech Company Detail
  • 11.8.2 Janssen Biotech Business Overview
  • 11.8.3 Janssen Biotech Breast Cancer Targeted Drug Introduction
  • 11.8.4 Janssen Biotech Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.8.5 Janssen Biotech Recent Development
  • 11.9 Bristol-Myers Squibb
  • 11.9.1 Bristol-Myers Squibb Company Detail
  • 11.9.2 Bristol-Myers Squibb Business Overview
  • 11.9.3 Bristol-Myers Squibb Breast Cancer Targeted Drug Introduction
  • 11.9.4 Bristol-Myers Squibb Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.9.5 Bristol-Myers Squibb Recent Development
  • 11.10 Gilead Sciences
  • 11.10.1 Gilead Sciences Company Detail
  • 11.10.2 Gilead Sciences Business Overview
  • 11.10.3 Gilead Sciences Breast Cancer Targeted Drug Introduction
  • 11.10.4 Gilead Sciences Revenue in Breast Cancer Targeted Drug Business (2017-2022)
  • 11.10.5 Gilead Sciences Recent Development
  • 12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
    • 13.2 Disclaimer
    • Summary:
      Get latest Market Research Reports on Breast Cancer Targeted Drug. Industry analysis & Market Report on Breast Cancer Targeted Drug is a syndicated market report, published as Global Breast Cancer Targeted Drug Market Research Report 2022. It is complete Research Study and Industry Analysis of Breast Cancer Targeted Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,688.30
      5,376.60
      3,016.00
      6,032.00
      418,586.00
      837,172.00
      236,437.00
      472,874.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report